Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
RESEARCH TOOLSreports
Mineralys Therapeutics, Inc. (MLYS) Stock Price & Analysis
231 Followers
MLYS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.85 - $17.44
Previous Close$13
Volume45.21K
Average Volume (3M)143.56K
Market Cap
$645.43M
Enterprise Value$596.13M
Total Cash (Recent Filing)$49.30M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-6.0
Beta2.13
Next Earnings
Aug 05, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding49,648,540
10 Day Avg. Volume187,629
30 Day Avg. Volume143,559
Standard Deviation0.21
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)2.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-26.96
Forecast
1Y Price Target
$31.25Price Target Upside140.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Mineralys Therapeutics, Inc. News
PremiumStock Analysis & Ideas
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Mineralys Therapeutics Board Member Announces Departure
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Advance-HTN study is considered relatively derisked, potentially enriching patient response to the treatment.
Drug EfficacyExperts anticipate a significant reduction in systolic blood pressure from the Advance-HTN study, comparing favorably with other agents.
Financial StabilityMineralys Therapeutics reported earnings with substantial cash reserves, expected to fund operations well into the future.
Bears Say
Clinical Trials UncertaintyQuestions on readthrough between trials and risk associated with standardizing background treatment.
Financial Performance1Q Operating Expenses increased by 28% driven by increased clinical trial costs.
Rising CostsOperational expenses are expected to increase due to the cost of rollover of hypertension and chronic kidney disease patients to ongoing studies, impacting the company's short-term financials.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $5.85 and its highest was $17.44 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2024 which is in 79 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on May 09, 2024. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.032.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -$0.7.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 49,648,540 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -2.594%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Among the largest hedge funds holding Mineralys Therapeutics, Inc.’s share is RA Capital Management. It holds Mineralys Therapeutics, Inc.’s shares valued at 63M.
---
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.25 (140.38% Upside)
$31.25 (140.38% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.5%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.85%
12-Months-Change
Fundamentals
Return on Equity
-29.11%
Trailing 12-Months
Asset Growth
13.32%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
---
MLYS Earnings Call
Q1 2024
0:00 / 0:00
---
MLYS Stock 12 Month Forecast
Average Price Target
$31.25
▲(140.38% Upside)
Technical Analysis
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-11.03%
initiated a buy rating 2 months ago
Copying Richard Law CFA's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.03% per trade.
---